A common problem in Phase II clinical trials is the comparison of dose response curves corresponding to different treatment groups. If the effect of the dose level is described by parametric regression models and the treatments differ in the administration frequency (but not in the sort of drug) a reasonable assumption is that the regression models for the different treatments share common parameters. This paper develops optimal design theory for the comparison of different regression models with common parameters. We derive upper bounds on the number of support points of admissible designs, and explicit expressions for D-optimal designs are derived for frequently used dose response models with a common location parameter. If the location and scale parameter in the different models coincide, minimally supported designs are determined and sufficient conditions for their optimality in the class of all designs derived. The results are illustrated in a dose-finding study comparing monthly and weekly administration.
Introduction
Adequately describing the dose-response relationship of a pharmaceutical compound is of paramount importance for achieving a successful clinical development. Sacks et al. (2014) recently conducted a review of the reasons for delay or denial of approval of drugs by the Food and Drug Administration (FDA). For those drug submissions that were not approved in the first-time application, one of the most frequent deficiencies was a statistical uncertainty related to the selected dose, illustrating the importance of clearly determining an efficacious and safe dose in Phase II dose-finding trials. Efforts to improve this situation have led to the introduction of dose-response modeling approaches in a prospective manner as the primary analysis method in dose finding studies, and have become increasingly widespread in the past few years [see among many others, Grieve and Krams (2005) , Bretz et al. (2005) , Thomas (2006) , Dragalin et al. (2007) , Bornkamp et al. (2007) , Thomas et al. (2014) ]. These methods can more adequately address the main questions of interest in Phase II dose-finding studies (i.e. determination of the dose-response curve and estimation of target doses of interest) than AN(C)OVA based pairwise comparisons. Moreover, it was pointed out by numerous authors that an appropriate choice of the experimental conditions can improve the statistical accuracy in dose-finding studies substantially. For this reason there exists a large amount of literature discussing the problem of constructing optimal experimental designs for regression models, which are commonly used to describe the dose relationships [see Dragalin et al. (2007) , Dette et al. (2008) , Dragalin et al. (2008) , Fang and Hedayat (2008) , Gilbert (2010) , or Bretz et al. (2010) among many others]. For many compounds a question closely related to "dose", the amount of drug, is the administration frequency of the drug. In most situations it is not adequate to assume that the same amount of drug per time unit (e.g. total daily dose) administered at different dosing intervals (e.g. once a day or twice a day) will lead to the same pharmacological effect. For example for once a day administration the drug exposure inside the body will generally be higher just after administration and lower just before the next administration, compared to a twice a day administration, where the same amount of drug is split into two doses in the morning and the evening, leading to more uniform drug exposure over the day. These considerations often lead to the need of evaluating the question of finding the right dose as well as dosing frequency dose-finding studies in Phase II. One way of modeling the dose-response curves in the different treatment groups is to estimate the dose response curve corresponding to each of them separately. This can, however, be wasteful as certain aspects of the dose-response curves for different group can be similar for both groups, suggesting a borrowing of strength. When dose-response modeling is done in terms of parametric dose-response models, one can often assume that certain parameters of the dose-response curves for the two (or more) groups are shared, while other parameters might be assumed to be different between the curves. is used to model the dose response relationship for both groups [see Gabrielsson and Weiner (2007) or Thomas et al. (2014) ], it is often reasonable to assume that the placebo effect is the same between groups, that is θ
0 = ϑ 11 . In some situations it might also make sense to assume that the maximum efficacy for high doses is similar, i.e. θ
(1)
1 = ϑ 12 , as a biological maximum attainable effect might exist. However it might not be adequate to assume that the dose providing half of the maximum efficacy is the same for different treatment frequencies, which means θ
(1) 2 = θ (2) 2 . The common parameters can then be estimated more precisely allowing for a more accurate statistical analysis. An example motivating the research of this paper can be found in Section 5. The major question when planning such a dose-finding study then is which doses to utilize in the different treatment groups and how to split the total sample size between the groups. Statistically, this corresponds to the construction of optimal designs for different regression models (modeling the effect of the drug in the different groups) which share some common parameters. To our best knowledge, design problems in this case have not been considered in the literature, and the goal of the present paper is to derive optimal designs for such situations. In Section 2 the model (in the context of M treatment groups) is introduced and the main differences between the situation considered in the paper and the common optimal design problems are explained. In Section 3 we derive some results on the comparison of different designs for regression models with common parameters with respect to the Loewner ordering. In particular we generalize recent results of admissible designs as presented in Yang (2010) , Dette and Melas (2011) and Yang and Stufken (2012) and derive upper bounds on the number of support points which cannot be improved upon in the Loewner ordering. Section 4 is devoted to the construction of D-optimal designs which are well suited for a "global" inference as they minimize the maximum confidence interval length around the predicted dose-response curve. Explicit expressions for locally D-optimal designs for the commonly used dose response models are derived, if some parameters of the models for the different groups coincide. We also discuss minimally supported optimal designs and investigate if these designs are optimal within the class of all designs. In Section 5 we illustrate the developed methods in a particular clinical dose-finding study investigating two different treatment groups. Finally, all technical details and proofs are given in Section 6 while Section 7 provides some more background on the modeling problem discussed in Section 5. For the sake of brevity and transparency, most parts of this paper consider locally optimal designs which require a-priori information about the unknown model parameters if the models are nonlinear [see Chernoff (1953) ]. In several situations preliminary knowledge regarding the unknown parameters of a nonlinear model is available but not in a form that is accurate enough to specify one parameter guess. As illustrated in Section 5, locally optimal designs can be used as benchmarks for commonly used designs and also serve as basis for constructing optimal designs with respect to more sophisticated optimality criteria, which are robust against a misspecification of the unknown parameters (and model) [see Pronzato and Walter (1985) or Chaloner and Verdinelli (1995) , Dette (1997) among others]. Following this line of research the methodology introduced in the present paper can be further developed to address uncertainty in the preliminary information on the unknown parameters, and we will illustrate this approach in Section 5, where we also discuss robust designs for the data example under consideration.
Models with common parameters
Consider the regression models
where ε ij are independent centered normally distributed random variables, i.e. ε ij ∼ N (0, σ 2 i ). The assumption of a normal distribution in (2.2) is made for the sake of transparency. Other distributional assumptions can be treated exactly in the same way. This means that M different groups are investigated and in each group observations are taken at different experimental conditions d
j the experimenter can take n ij observations and n i = k i j=1 n ij denotes the number of observations in the i-th group (i = 1, . . . , M ). Moreover, the total sample size is given by n = M i=1 n i . In general, the regression model f (·, θ 1 , θ
2 ) is used to describe the dependency between the response and the effect in every group. We consider the same parametric form for all groups. Moreover, the parameter vector θ 1 ∈ R p is assumed to be the same in all groups (i = 1, . . . , M ), while θ
is different for different groups. Consequently, the vector of unknown parameters is given by θ = (θ 1 , θ
) ∈ R m , where m = p + qM . The components of the vector are denoted by Following Kiefer (1974) we define for i = 1, . . . , M approximate designs ξ i (on the design space X i ) as probability measures with masses ξ ij at the experimental conditions d (i) j ∈ X i (j = 1, . . . , k i ) and a design µ as a probability measure on the set {1, . . . , M } assigning mass λ i to the ith group. We collect these designs in the vector ξ = (ξ 1 , . . . , ξ M , µ), which is also called design (on the design space X 1 × . . . × X M × {1, . . . , M }) throughout this paper. If an approximate design ξ = (ξ 1 , . . . , ξ M , µ) is given and N observations can be taken, a rounding procedure is applied to obtain integers n i and n ij (i = 1, . . . M, j = 1, . . . , k i ) from the not necessarily integer valued quantities λ i n and ξ ij n i , respectively [see Pukelsheim and Rieder (1992) ]. Then, under common assumptions of regularity and the assumption
where the symbol D − → denotes weak convergence. Here the matrix
is called the information matrix of the design ξ = (ξ 1 , . . . , ξ M , µ) and will be derived in Section 6.1. In (2.4) the matrices M (i) are defined by
2 ) with respect to the parameter θ ∈ R m , where, m = p + qM , 0 q ∈ R q denotes a vector with all entries equal to 0.
Example 2.1 We assume that M = 2 and that the regression functions f (·, θ 1 , θ
2 ) can be written as
with a given function f 0 [see Bretz et al. (2005) ]. Here the location and scale parameters θ 1 = (ϑ 1 , ϑ 2 ) T ∈ R 2 are the same for all groups, while the parameters θ (i) 2 ∈ R q are different. In this case we have p = 2 and the vectors h 1 (d) and h 1 (d) are given by
2 ),
2 ), 0
2 ) .
As a further example, consider a regression function f (·, θ 1 , θ
with a given function f 0 . If the location parameter θ 1 is the same for the two groups and the parameters θ (i) 2 ∈ R q are different, we have p = 1 and the vectors h 1 (d) and h 1 (d) are given by
2 )).
Comparing designs in the Loewner ordering
An optimal design ξ = (ξ 1 , . . . , ξ M , µ) maximizes a concave real valued function, say Φ, of the information matrix. Numerous criteria have been proposed in the literature (see Pukelsheim (2006) among others) which can be used to discriminate between competing designs and the particular case of D-optimality will be discussed in the subsequent section. The commonly used optimality criteria are monotone with respect to the Loewner ordering, that is the relation
For this reason we discuss at first some results for this ordering, which will be very helpful for the explicit determination of optimal designs in the following sections. Throughout this paper let |A| denote the cardinality of a set A and we denote by supp(ξ) the support of the design ξ = (ξ 1 , . . . , ξ M , µ). Moreover, we define the index I(ξ i ) of the design ξ i on the interval [0, d (i) max ] as the number of support points, where the boundary points 0 and d (i) max are only counted by 1/2 if they are support points of the design ξ i (i = 1, . . . , M ). Note that the gradient (2.6) can be rewritten in the form
where P i is a (p + M q) × (p + q) block matrix, I p×p is the p-dimensional identity matrix and
2 ) with respect to (θ 1 , θ
2 ) (i = 1, . . . , M ). Consequently, for the information matrix (2.5) the representation
holds, where the (p + q)
2 ) is defined by
In the following we will present a generalization of results in Yang (2010) , Dette and Melas (2011) and Yang and Stufken (2012) . To be precise for i = 1, . . . , M we define Ψ 0 (d) ≡ 1 and choose a basis, say
2 )|1 ≤ s, t ≤ p + q} ∪ {1}), where the dependence on the parameters is reflected by the upper index i for the sake of a transparent notation. We also assume that the function Ψ
2 ), does not coincide with any of the other elements Ψ s,t (·, θ 1 , θ 
Lemma 3.1
max ], then for any design ξ there exists a design 
the design coincides with the design ξ. In the case
, the following two assertions are valid. 
are Chebychev systems for the different groups i = 1, . . . , M . Note that this bound is the same independently from the dimension of θ 1 , since the number of support points is bounded in every group 1, . . . , M separately. The next lemma shows that (for the commonly used dose response models) it is sufficient to allocate only patients from the group with the smallest population variance to placebo.
Lemma 3.2 Assume that the design spaces are given by
max ] (i = 1, . . . , M ) and that the regression models are given by (2.7) or by (2.8), where the function f 0 is differentiable with respect to θ (i) 2 (i = 1, . . . , M ). Moreover, assume that f 0 (0, θ 2 ) = 0 and
. . , η M , ν) denotes a design with 0 ∈ supp(η j ) for (at least) one index j, then there exists a design ξ = (ξ 1 , . . . , ξ M , µ) with the following properties
2 ) − 1) (3.4) location and scale
2 ) − 1 (3.7) Table 1 : Commonly used dose response models for i = 1, . . . , M . Left column: The placebo effect is the same in every group (common location). Right column: Both the placebo effect and the scale parameter coincide in every group (common location and scale).
In the following discussion we will apply the previous results to some of the commonly used dose response models, namely the Emax model, linear-in-log and exponential model [see Gabrielsson and Weiner (2007) ], which are listed in Table 1 . In this table we also illustrate our notation again. The left part of the table corresponds to a model with a common location parameter (namely θ 1 ), while the right part of the table shows a model with a common location (ϑ 1 ) and scale parameter (ϑ 2 ). We note that all these models satisfy the conditions of Lemma 3.1 and Lemma 3.2.
(1) If the regression model is given by the Emax model (3.2) or (3.5), then there exists a design
Moreover, ξ + can be chosen such that |supp(ξ
max ∈ supp(ξ + 1 ) and |supp(ξ
(2) If the regression model is given by the linear-in-log model (3.3) or (3.6), then there exists a design ξ
(3) If the regression model is given by the exponential model (3.4) or (3.7), then there exists a design ξ
Moreover, ξ + i can be chosen such that |supp(ξ
D-optimal designs
When one of the major purposes of the study is to determine the dose-response curve, D-optimal designs are well suited as they minimize the maximum confidence interval length around the predicted dose-response curve [see Silvey (1980) ]. Following Chernoff (1953), a design ξ = (ξ 1 , . . . , ξ M , µ) is called (locally) D-optimal for the information matrix given in (2.4) if it maximizes the determinant of the information matrix det(M (ξ, θ)) in the class of all designs ξ on
A main tool of optimal design theory are equivalence theorems which, on the one hand provide a simple checking condition for the optimality of a given design, and on the other hand, are the basis of many procedures for their numerical construction. Moreover, these characterizations of optimality can also be used to derive structural properties of optimal designs. The following result provides the equivalence theorem for the D-optimality criterion corresponding to the matrix given in (2.4). The proof follows by standard arguments of optimal design theory and is therefore omitted.
as the set of all designs on X 1 × . . . × X M × {1, . . . , M } with exactly m different dose levels in the M groups. The proof of the next lemma follows by similar arguments as in the standard case [see Silvey (1980) among others], and is therefore also omitted.
If ξ is locally D-optimal in the class Ξ M m , then each component ξ i has equal weights at its support points. Moreover, the weights of µ at the points 1, . . . , M are given by
In the following two sections we present some locally D-optimal designs for the Emax, the exponential and the linear-in-log model. The proofs of these results are complicated and therefore deferred to Section 6.
Models with the same location parameter
First, we consider the case where only the location parameter is the same in the different models. In applications this reflects the situation of a common placebo effect for all groups (cf. the first column of Table 1) , and we are able to identify the locally D-optimal design explicitly. We begin with a general result for the regression functions of the form (2.8) where the unknown parameter vector is given by θ = (θ 1 , θ
The following result provides a solution of the D-optimal design problem if the D-optimal design for the single models are known.
i and consider the model given by (2.8), which satisfies
2 ) (i = 1, . . . , M ), then the locally D-optimal design for model (2.8) is given by ξ = (ξ 1 , . . . , ξ M , µ ) where
Using Theorem 4.3 the placebo effect θ 1 is estimated in the group where the variance is smallest (see also Lemma 3.2 and Corollary 3.3). Moreover, it follows from the proof of Lemma 3.2 that the D-optimal design given by Theorem 4.3 is not unique if there exist two groups, say j * 1 and j * 2 , with σ
We now use these results to determine D-optimal designs for the Emax, exponential and linear-in-log model explicitly.
The locally D-optimal design for the Emax, exponential and linear-in-log model (3.2) is of the form ξ = (ξ 1 , . . . , ξ M , µ ), where
and the point x ,(i) is given by
for the Emax model, by
for the exponential model and by
for the linear-in-log model.
It is worthwhile to mention that the locally D-optimal design for model (2.8) with an Emax curve consists of the designs which are locally D-optimal for the models given by an individual Emax model with parameter (θ 1 , θ
2 ) and by an Emax model with location parameter equal to zero and parameter θ (i) 2 , i = 2, . . . , M . This effect can also be observed for the exponential and the linear-in-log model.
Models with the same location and scale parameters
In this section we consider model (2.7) and assume that the location and scale parameter coincide across the different models (cf. the second column in Table 1 ). It turns out that in this case the D-optimal design problem is substantially harder, and for the sake of a transparent presentation, we restrict ourselves to the case of M = 2 groups. Similar results can be obtained in the case M > 2 with an additional amount of notation. We begin with some general properties of locally D-optimal designs for the model (2.7) in the case of an Emax, linear-in-log and exponential curve. For this purpose we define
as the ratio of the two population variances.
Lemma 4.5
(A) The locally D-optimal design ξ = (ξ 1 , ξ 2 , µ) for the Emax model (3.5) and the linear-in-log (3.6) have the following properties:
(B) The locally D-optimal design ξ = (ξ 1 , ξ 2 , µ) for the exponential model (3.7) satisfies |supp(ξ 1 )| + |supp(ξ 2 )| ∈ {4, 5, 6}.
By the previous lemma the number of support points of the locally D-optimal designs is at most 5 for the Emax and linear-in-log model and at most 6 for the exponential model. On the other hand, at least four support points are required to estimate all parameters in both models (note that the scale and location are assumed to be the same throughout this section). In the following discussion we determine such "minimally" supported D-optimal designs explicitly for the Emax, exponential and linear-in-log model.
Minimally supported designs
Recall the definition of the set Ξ M m in (4.2). We call a design of the ξ = (ξ 1 , ξ 2 , µ) minimally supported (for the Emax, linear-in-log and exponential model) if ξ ∈ Ξ 2 4 (note that for these models the information matrix is of size 4 × 4 as the scale and location parameter coincide in both models). It turns out the the minimally supported D-optimal designs for the three models under consideration have a very similar structure. On the other hand the question, if these designs are D-optimal in the class of all designs does not have a simple answer and will be discussed in the following section.
emax by (4.6) (i = 1, 2).
(1) If r ≤ 1, the locally D-optimal design for model (3.5) in the class Ξ 
1+θ
(1) 2
6
, the locally D-optimal design for model (3.5) in the class Ξ 
1+θ
6
, the locally D-optimal design for model (3.5) in the class Ξ 2 4 is given by We can also obtain the minimally supported D-optimal designs for the exponential model and the linear-in-log with common location and scale parameter.
Theorem 4.7 Letθ
max and the point x
exp by (4.7) for i = 1, 2.
(1) If r ≤ 1, the D-optimal design for model (3.7) in the class Ξ 2 4 is given by (4.9).
, the D-optimal design for model (3.7) in the class Ξ 2 4 is given by (4.10).
, the D-optimal design for model (3.7) in the class Ξ 2 4 is given by (4.11).
Theorem 4.8 Letθ
log by (4.8) for i = 1, 2.
(1) If r ≤ 1, the D-optimal design for model (3.6) in the class Ξ 2 4 is given by (4.9).
, the D-optimal design for model (3.6) in the class Ξ 2 4 is given by (4.10).
, the D-optimal design for model (3.6) in the class Ξ 2 4 is given by (4.11).
D-optimal designs in the class of all designs
The question if a minimally supported D-optimal design for one of the models considered in Section 4.2.1 is in fact D-optimal in the class of all designs is an extremely difficult one. Its answer depends sensitively on the particular parameters in the model under consideration and differs for the three dose response models under consideration. We exemplarily state a result for the Emax model, which provides sufficient conditions for the D-optimality of a minimally supported D-optimal design, and illustrates the general structure and difficulties in results of this type. The proof is based on the equivalence Theorem 4.1 and given in the appendix. Similar but substantially more complicated statements can also be obtained of the linear-in-log and the exponential model (note that in contrast to the Emax model these models contain transcendental functions). (1) Let r ≤ 1. The design ξ a, defined in (4.9) is locally D-optimal for model (3.5) if the conditionθ
2 ≥ r 6θ
2 + 1)(2θ
2 (1 + 2θ
2 )) (4.12)
is satisfied. . The domain for the first case of Theorem 4.9 is represented in gray for the case r = 1/10, r = 1/2 and r = 1 (see the first three panels from the left). In the right panel we display the case r = 2 of Theorem 4.9 (here the gray region corresponds to case (2), while the dark gray region corresponds to case (3)). 
2 ) 2 (1 + 2θ
2 ) 2 + r(1 +θ
2 ) 2 (1 + 4θ
(1) 2 + 20(θ
2 ) 2 ) − 1 6 + 2θ
2 ) (4.13)
is satisfied.
(3) Let r > 1. The design ξ c, defined in (4.11) is locally D-optimal for model (3.5) if the
2 )) (4.14)
is satisfied. . The case where the variance is equal in both groups is presented in the third panel. Obviously, there are several parameter constellations θ
2 where the minimally supported D-optimal design ξ a, is not optimal in the class of all designs.
Application to a dose-finding study
In this section we illustrate the application of the results of the previous sections and discuss the problem of designing experiments for a dose finding study with different treatment groups. Our example refers to a Phase II study on a drug that works by increasing the level of a biomarker that induces a beneficial clinical effect in patients. The dosing groups under consideration are monthly and weekly administration. The primary objective of the study is the characterization of dose-response relationships at a given time-point, say T , after initiation of treatment for each of these two dosing groups. This will support the selection of an appropriate dose level and group to be used in phase III clinical trials. To maintain the confidentiality of the trial the dose-range has been rescaled and the considered range (in terms of total monthly dose) is [0, 400] for the weekly group and [0, 1000] for the once-a-month group. The natural questions for the design of this study are (i) which doses should be studied in each treatment group and (ii) how to split the total sample size between the two treatment groups. Here the objectives of the study are addressed by deriving the best estimates of the dose response curves, a task for which a D-optimal design is best suited. To arrive at a suitable design for the Phase II study, we need to quantify the information. This quantification can generate a best guess for the dose-response curves, but, even better, it can be used to obtain a candidate set of dose-group-response scenarios to reflect the uncertainty about the true dose-group-response relationship. The available information was data from a very small early trial, which was used to develop a nonlinear mixed effects pharmacokinetics (PK) / pharmacodynamics (PD) model linking drug concentrations to biomarker levels. Using this model, data of the new trial were predicted for the time-point T of the dose-response analysis and dosegroup-response models were fitted to the data. Under the assumption of a normal distribution for the logarithm of the biomarker level, it turned out that the Emax function was able to adequately describe the population average predicted by the PK/PD model. The Emax model utilized total monthly dose as input and had different ED 50 parameters in the two groups (θ
2 and θ
2 ), but the same placebo ϑ 11 and Emax parameter ϑ 12 , so that the model function in the weekly and monthly group is given by
Here group i = 1 contains patients receiving monthly administration and the group i = 2 the weekly administration. The parameter estimates can be found in Table 2 as model 1, which can be considered as population average fit. We now use these estimates as a guess and determine the locally D-optimal design for these values. The variability is expected to be the same in both treatment groups. Recalling the design spaces for the monthly and weekly doses are X 1 = [0, 1000] and X 2 = [0, 400], respectively, we obtain from Theorem 4.6 and Theorem 4.9 the (locally) D- Candidate models for the dose-response curve in monthly and weekly group. In the first row models 1-5 are depicted and in the second row models 6-10 (see Table 2 ). The solid line represents the population average of the new trial data generated with the PK/PD model. The grey area represents the biomarker level between the 25th and 75th quantiles of the patient responses of the new trial data. Dotted curves correspond to the Emax models. Sigmoid Emax models are depicted as dotted-dashed lines and the linear-in-log models as dashed lines.
optimal design ξ = (ξ 1 , ξ 2 , µ ) as .
It can be seen that based on the population average fit, it is sufficient to investigate the low dose-range in both groups and a high dose in one of the two groups. Here the maximum dose is placed in the monthly group because θ
max , so relative to the allowed maximum dose a larger ED 50 parameter exists for the weekly group and thus patients are allocated to the monthly group. In practice, it is not realistic to assume that the data and model from previous small trials completely represent the underlying truth (otherwise no further study would need to be conducted). So it is important to derive ranges covering the uncertainty about the available information to use for the design of the new study. In particular, because the population to be included in the Phase II trial will cover a broader range of characteristics than in the small proof of concept trial. For this purpose the PK/PD model was used to predict individual dose-response curves and model type id ϑ 11 ϑ 12 θ Table 2 : Set of candidate models used in the robust criterion (5.1) the Emax model was fitted to the individual dose-response curves to derive a range of plausible dose-response parameters. Quantiles of the derived parameter distributions were used to derive four additional candidate model shapes. More details on how these candidate shapes were derived can be found in Appendix 7. The parameters for these four additional candidate models can be found in Table 2 under the numbers 2-5. These models are depicted in the first row of Figure 2 . With this set of candidate models, the design maximizing the mean efficiency
can be calculated, where s is the number of candidate models (here 5 or 10), π 1 , . . . , π s are nonnegative model weights chosen to reflect prior probability associated the model function 1, . . . , s (throughout this paper we will use π i = 1/s, i = 1, . . . , s). The efficiencies Eff i (ξ) of the experimental design ξ with respect to the (locally) D-optimal design ξ ,i associated to the model i is defined as
where M i is the Fisher information matrix associated to the model i with parameter specification θ i and m i is the number of parameters of this model. The criterion (5.1) is called Bayesian or compound optimality criterion in the literature [see Dette (1990) , Cook and Wong (1994) or Tsai and Zen (2004) ; Zen and Tsai (2004) among many others]. In the following we will denote the designs maximizing (5.1) by ξ c,s = (ξ 1,c,s , ξ 2,c,s , µ c,s ) and call it compound optimal design. We emphasize that the definition of the criterion (5.1) requires knowledge of the locally optimal designs ξ ,i , which have been determined in Section 4.
The compound optimal design based on the first 5 models in Table 2 can be calculated numerically  and is , and its optimality can be proved by an analogue of Theorem 4.1 for the Bayesian optimality criterion (5.1). Compared to the design using only the best guess model, now the low dose-range is investigated in finer granularity by using two instead of one dose (safeguarding against different possible values of the ED 50 ). In addition still more patients are evaluated for the monthly group, as the high dose is only used there. Based on general plausibility considerations five further candidate shapes were included as example of models different from the Emax function (e.g. the sigmoid Emax and the linear-in-log function), or of models where the maximum efficacy differed between the two groups. These models are shown in the second row of Figure 2 and the corresponding parameters are given in the rows with ids 6-10 in Table 2 . First a sigmoid Emax model
with Hill coefficient γ = 3 (model 6) is also considered as a possible dose response function. Note that this model provides a steeper dose-response curve compared to the Emax model, but with the same ED 50 values as model 1. Furthermore, an Emax and a sigmoid Emax model
is added that allows for different Emax parameters in the two treatment group (models 7, 8, 9) . In addition a linear-in-log model (id 10) is utilized. The locally D-optimal designs for these models can be computed using the results of Section 4. For the sigmoid Emax models, a transformation has to be used to reduce it to the case of an Emax model, such that the derived theory is applicable (note that the parameter γ is assumed to be fixed). When using all s = 10 candidate models we obtain ξ c,10 = (ξ 1,c,10 , ξ 2,c,10 , µ c,10 ) where This design investigates the lower dose range comparably to the previous design based on the first five candidate models, but the maximum dose is studied in both groups. The efficiencies of the Table 3 : Efficiency Eff i (ξ c,s ) of the two compound optimal designs compared to each of the locally D-optimal designs for the 10 models.
two designs ξ c,5 and ξ c,10 in the different models are displayed in Table 3 . We observe that the design ξ c,5 has reasonable efficiencies in all models except in the sigmoid Emax (6). Note that this design has been constructed on the basis of the models (1) -(5). On the other hand the the design ξ c,10 maximizes the criterion (5.1), where uncertainty with respect to all models (1) - (10) is addressed. As a consequence this design has efficiencies varying between 75% -90% in all competing models under consideration. Moreover, it can be used for a goodness-of-fit test of the Emax model, as both components have more than 3 support points. For these reasons we recommend this design for the Phase II study under consideration.
6 Appendix: technical details
Deviation of the information matrix
Assuming a normal distribution of the errors (ε ij ∼ N (0, σ 2 i ) independent) partial derivatives of the corresponding log-likelihood function (θ) with respect to θ 1 and θ (i) 2 are given by
where
2 ). Consequently, we obtain for the Fisher information
where the vector h i is defined in (2.6). Observing the assumption (2.3) it follows that 1 n M n converges to the matrix M (ξ, θ) defined in (2.4).
Proof of main results
Proof of Lemma 3.1: We only discuss the first part of the proof. The second assertion follows by similar argument. Let ξ = (ξ 1 , . . . , ξ M , µ) be an arbitrary design with |supp(ξ i )| ≥ 
2 ) for all i = 1, . . . , M . Recalling the definition of the matrix P i in (3.1) it then follows by Theorem 14.2.9 of Harville (1997) that
This implies
and the design ξ + increases the information matrix M (·, θ) with respect to the Loewner ordering.
It now follows from Theorem 3.1 of Dette and Melas (2011) support points (i = 1, . . . , M ). The statements (1a) and (1b) in Lemma 3.1 also follows from Theorem 3.1 in Dette and Melas (2011).
Proof of Lemma 3.2:
We only prove the Lemma for the model given by (2.7). The proof for model (2.8) is analogous. Note that in the model under consideration we have
2 ) for the gradient in (2.6). Consequently, if δ 0 denotes the Dirac measure at the point 0, it follows for the matrices M (i) defined in (2.5) that
Now, we consider the design η = (η 1 , . . . , η M , ν) and represent its components as
Here δ t is the Dirac measure at the point t, λ i , ω 
0 > 0. We now assume without loss of generality that j * = 1 and construct a "better" design ξ = (ξ 1 , . . . , ξ M , µ) as follows
Note that we shift the weights of the measures η i at the point 0 to the design for the group with the smallest population variance. Observing (6.1) gives for the difference Proof of Theorem 4.3: For the sake of transparency we restrict ourselves to the case M = 2 such that m = M q +1 = 2q +1. We use the equivalence Theorem 4.1 to establish the D-optimality of the design ξ . In the present situation this means that the D-optimality of the design ξ defined in (4.5) for model (2.8) with assumption (4.3) can be proved by checking the two inequalities
2 )
max ], (6.3)
2 ). A straightforward calculation shows that the information of the design ξ can be represented as
2 )X T (σ 1 , θ
2 , σ 2 , θ
2 ) , (6.4)
where the matrix X(σ 1 , θ
2 ) is given by
2 ) =
1 , . . . , d
, and the matrices X 11 σ, 0, d
q , θ
2 ) ∈ R q×q and X 12 (σ) ∈ R (q+1)×q are defined by
2 ) = 1
2 ), . . . , η 0 (d
2 ) ,
1 , . . . d
2 ) = 1 σ 1 1
, X 12 (σ) = 1 σ
Consequently, the inverse of M (ξ , θ) is obtained as
2 ))
2 ), where
2 ) = X −1
.
Using these block structures the function κ 1 (t, ξ , θ) defined in (6.2) reduces for the design ξ = (ξ 1 , ξ 2 , µ ) to
2 ) T ,
2
2 ) dξ 1 (t) denotes the information matrix of the design ξ 1 in the single model with parameter (θ 1 , θ (1) 2 ). Consequently, the function κ 1 (t, ξ , θ 1 , θ
( 1) 2 ) only depends on the first component ξ 1 and is proportional to the left-hand side of the standard equivalence theorem for D-optimality for the single model. The inequality κ 1 (t, ξ , θ) ≤ m for all t ∈ [0, d
( 1) max ] follows from the fact that the design ξ 1 given in (4.4) is locally D-optimal for the single model with parameter (θ 1 , θ
( 1) 2 ) and this proves (6.2). In order to show the remaining inequality (6.3) for all t ∈ [0, d
( 2) max ] we use the fact that the information matrix in (6.4) can be represented as
2 , σ 1 , θ
2 )S, where S denotes a m × m permutation matrix, defined by
0 q×q denotes a matrix with all entries equal to zero and I q×q the q × q identity matrix. Observing that Sh 2 (t) =
2 ), 0 T q T it follows that the function κ 2 (t, ξ , θ) in (6.3) can be represented as
2 ) X −1
(2)
2 ) is the information matrix of the designξ 2 given by (4.4) for the single model. The first term of this expression is proportional to the left hand side of the equivalence theorem corresponding to the D-optimality in the single model with parameter (θ 1 , θ (2) 2 ). Moreover, it follows that the designξ 2 is D-optimal for the single model with parameter (θ 1 , θ (2) 2 ), which implies that the first term is always smaller than m. By the assumption σ 2 1 ≤ σ 2 2 we obtain that the second term of this expression is nonpositive, which shows κ 2 (t, ξ , θ) ≤ m for all t ∈ [0, d Proof of Lemma 4.5: Let ξ = (ξ 1 , ξ 2 , µ ) denote the locally D-optimal design for the Emax, the linear-in-log or the exponential model. Since the information matrix M (ξ , θ) of a locally D-optimal design must be nonsingular one can easily deduce the following implications
Moreover, it follows by Corollary 3.3 that the locally D-optimal design has at most 5 support points for the Emax and the linear-in-log model and at most 6 support points for the exponential model. This proves Assertion (A1) and (B). Assertion (A2) also follows by Corollary 3.3. For a proof of (A3) we note that (|supp(ξ 1 )|, |supp(ξ 2 )|) ∈ {(1, 3), (2, 2), (3, 1)} if the locally Doptimal design is given by a design in Ξ max , otherwise it could be improved with respect to the Loewner ordering (see Theorem 3.1). If (|supp(ξ 1 )|, |supp(ξ 2 )|) = (2, 2), both designs must contain at least one of the boundary points, otherwise I(ξ i ) = 2 (i = 1, 2) and the designs could be improved with respect to the Loewner ordering (see again Theorem 3.1). Using (6.6) it follows that at least one of the designs contains the corresponding upper boundary point. If (|supp(ξ 1 )|, |supp(ξ 2 )|) = (3, 1), ξ 1 must contain the boundary points 0, d
(1) max , otherwise it could be improved with respect to the Loewner ordering (see Theorem 3.1). Assertion (A3) now follows.
Proof of Theorem 4.6: For the sake of brevity we restrict the discussion to the Emax model. The proof consists of two steps. At first we show that it is sufficient to prove the result on the design space [0, 1] . Secondly, we determine the D-optimal design in the class Ξ 4 2 .
(1) Recall the definition of the information matrix in (2.4) (with M = 2) in model (3.5) with the parameter vector θ = (ϑ 11 , ϑ 12 , θ
T ∈ R 4 . Let ξ = (ξ 1 , ξ 2 , µ) denote an arbitrary design with components ξ 1 and ξ 2 defined on the design space [0, d
max ] and [0, d
max ], respectively, and denote byξ 1 andξ 2 the corresponding measures on the interval [0, 1] induced by the transformation
max (i = 1, 2). Now a straightforward calculation gives
is a 4×4 matrix. This shows that the components ξ 1 and ξ 2 of the locally D-optimal design for the Emax model on the design spaces [0, d respect to the support points. For example we obtain for the design D-optimal ξ a = (ξ
2 ) (d
Observing that θ
2 < 1 we obtain that the factor
2 ) 2 2 is maximized for d
2 , and it follows by a straightforward calculation that the support points of the design ξ a 1 and ξ a 2 in (6.7) maximizing the determinant are given by
respectively. The resulting determinant of the information matrix of the corresponding design, say ξ a, , is obtained as
Analogously, we get that the support points Finally, we consider the determinant of the candidate design (6.8), that is
2 ) 4 .
We assume without loss of generality that d 
2 )X −1
2 ) 0X
and we obtain for the function κ 1 (t, ξ a, , θ) in (6.12) the representation T . Because the design ξ a, 1 given in (4.9) is in fact locally D-optimal for this model, it follows that κ 1 (t, ξ a, , θ) ≤ 4, which proves the first inequality of the equivalence theorem.
In order to show that the inequality in (6.13) holds for all t ∈ [0, 1] we note that this inequality is equivalent to
2 ) 4 κ 2 (t, ξ a, , θ) − 4 = α 21 t 4 + α 22 t 3 + α 23 t 2 + α 24 t + α 25 ≤ 0, (6.14)
where the last identity defines the coefficients α 2j in an obvious manner. For example, the leading coefficient and the intercept are given by
2 (θ
2 ) 4 (
2 ) 4 r − 1 , respectively. Consider the case r < 1 (the case r ≤ 1 is finally obtained considering the corresponding limit) and note that P (0) = α 25 < 0. Consequently, (6.14) holds if either there are no roots of P in the interval (0, 1) or all roots of P in the interval (0, 1) have multiplicity 2. The roots of P (t) are easily calculated as
where we use the notation
2 ) 2 ) + 2r(1 + 6θ
2 ) 2 + 24(θ
2 ) 3 + 12(θ
2 ) 4 ) .
Note that s(θ
2 ) is positive (because θ
(1) 2 > 0 and r ≤ 1) and that θ (2) 2 ∈ (0, 1) is a root of multiplicity 2. Moreover, P (−θ (2) 2 ) > 0 (since M −1 (ξ a, , θ) is positive definite), and it follows from P (0) < 0 that P has a root in the interval (−θ
2 , 0). This is eitherd 1 ord 2 depending on the sign of the leading coefficient α 21 . The inequality (6.14) holds, if the other root is neither in (0, 1). In order to check the location of the rootsd 1 andd 2 we consider the condition (4.12) and the case that the right hand side of (4.12) is positive. This implies that the leading coefficient α 21 is positive and the rootd 2 is also positive. We obtain from the conditiond 1 ∈ (−θ Therefore it follows from (4.12) (with positive right hand side) that the inequalityd 2 ≥ 1 is satisfied.
On the other hand, if the right hand side of (4.12) is negative, the leading coefficient α 21 is negative and the conditions P (0) < 0 and P (−θ
2 ) > 0 imply that both rootsd 1 andd 2 must be negative, because otherwise the polynomial P does not satisfy (6.14). Observing thatd 2 <d 1 in this case, it is easy to see that the condition (4.12) (with negative right hand side) impliesd 1 < 0. Summarizing, in the case r ≤ 1 the inequality (4.12) implies (6.14) for all t ∈ [0, 1] and the D-optimality of the designs ξ a, follows by an application of Theorem 4.1.
(2) At first, we show that the condition (4.13) and r > 1 imply that 1 < r ≤ (1+θ
2 ) 6 (1+θ 
2 ) − 1 and we have to show that:
2 ) 2 + r(1 + θ
(1) 2 (1 + 2θ
> r 1/6 (1 + θ
2 ) − 1. (6.15) This inequality can be rewritten by (20r + 4)(θ
2 ) 4 + (44r − 6 √ r + 1)(θ
2 ) 3 + (29r − 6 6 √ r + 5)(θ
2 ) 2 + (6r − 8 6 √ r + 2)(θ
2 ) + (r − 6 6 √ r + 5) > 0.
Note that the coefficients of the polynomial are positive for all r > 1. It follows by the rule of Decartes that this polynomial has no positive roots and consequently, (6.15) is satisfied for all positive θ
2 . Thus, if r ≥ 1 and the inequality (4.13) holds, we investigate the D-optimality of the design ξ Analogously to the proof of part (1) it can be shown that the first inequality (6.16) is satisfied for all t ∈ [0, 1]. In order to establish the inequality (6.17) for all t ∈ [0, 1] we consider the polynomial
2 ) 4 κ 2 (t, ξ b, , θ) − 4 = α 21 t 4 + α 22 t 3 + α 23 t 2 + α 24 t + α 25 , where the leading coefficient and the intercept are now given by
2 ) = 4 (θ
( 1) 2 ) 2 + r(1 + θ
2 ) 2 ) − 4, α 25 = 4(θ 
2 ) which coincides with (4.13).
(3) At first, one can show that the condition (4.14) and r > 1 imply that r ≥ (1+θ . Then the result follows by similar arguments as given in the proof of part (1), which are omitted for the sake of brevity.
7 Appendix: Derivation of candidate models based on a preliminary PK/PD model
The PK/PD model was a nonlinear mixed effects longitudinal model describing the PK of the drug and linking this to the PD of the drug. The model was used to simulate longitudinal profiles per patient. The simulation took into account parameter uncertainty from the model fit. Then an Emax dose-group-response model was fitted to the cross-sectional data at time T , that assumed that the placebo and maximum effect of the curve are the same, but the ED 50 are different in the two group. First this model was fit to the whole population of simulations to give a population best guess, giving ϑ 11 = 5.48, ϑ 12 = 0.90, θ
(1) 2 = 13.82, θ
2 = 10.46. In addition 200 individual patient profiles were simulated (see Figure 3) and each individual doseresponse curve was fitted at time T to give 200 parameter estimates, representing the variability on the dose-response curve in the population. These 200 parameter sets are used to compute the distribution of each parameter (ϑ 11 , ϑ 12 , θ 2 ) and their summary statistics are given in Table  7 . The logarithm of biomarker Y was modeled to achieve a better approximation through the normal distribution. Based on that, we propose 4 extreme models using the 10% and 90% quantile for the ED 50 's parameter.
Figure 3: 200 simulated dose-response curves at timepoint T for monthly (group 1, right panel) and for the weekly (group 2, left panel) in grey. In red is the fit of the population dose-response curve.
